Sleep Aging and Risk for Alzheimer's 2.0



Status:Recruiting
Conditions:Alzheimer Disease, Insomnia Sleep Studies
Therapuetic Areas:Neurology, Psychiatry / Psychology
Healthy:No
Age Range:55 - 75
Updated:3/21/2019
Start Date:May 1, 2018
End Date:May 30, 2023
Contact:Ricardo Osorio, M.D
Email:ricardo.osorio@nyumc.org
Phone:212-263-3255

Use our guide to learn which trials are right for you!

Sleep Aging and Risk for Alzheimer's Resubmission 2.0

Age-related sleep changes and common sleep disorders like obstructive sleep apnea (OSA) may
increase amyloid burden and represent risk factors for cognitive decline in the elderly. We
will directly interrogate the brain using a 2-night nocturnal polysomnography (NPSG) and
amyloid deposition using C-PiB PET/MR both at baseline and at the 24-month follow-up. This
study has the potential to identify the mechanisms by which age-related sleep changes
contribute to AD neurodegeneration in cognitively normal elderly, the group that could profit
the most from sleep preventive strategies.


Inclusion Criteria:

To be eligible to participate in this study, an individual must meet all of the following
criteria:

- Male and female subjects with normal cognition and 55-75 years.

- Within normal limits on neurological and psychiatric examinations. All subjects
enrolled will have both a CDR=0 and a MMSE>26.

- All subjects will have had a minimum of 12 years of education. Among minority subjects
>80% of the elderly individuals coming to the NYU-ADC meet this criterion. The
education restriction reduces performance variance on cognitive test measures and
improves the sensitivity for detecting pathology and disease progression using the
robust norms available at NYU. Given most subjects will meet this criterion we do not
consider this a major selection bias or generalization limitation for this study.

- An informed family member or life-partner (preferably bed-partner) will be interviewed
to confirm the reliability of the subject interview.

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation
in this study:

- History of brain tumor, MRI evidence of brain damage or brain disease including
significant trauma, hydrocephalus, seizures, mental retardation or other serious
neurological disorder (e.g. Parkinson's disease or other movement disorders).

- Significant history of alcoholism or drug abuse.

- History of psychiatric illness (e.g., schizophrenia, bipolar, PTSD, or life-long
history of major depression).

- Geriatric Depression Scale (short form)>6.

- Insulin dependent diabetes.

- Evidence of clinically relevant cardiac, pulmonary, endocrine or hematological
conditions.

- Physical impairment of such severity as to adversely affect the validity of
psychological testing.

- Any prosthetic devices (e.g., pacemaker or surgical clips) that constitutes a hazard
for MRI imaging.

- Medications affecting cognition: Narcotic analgesics, chronic use of medications with
anticholinergic activity, anti-Parkinsonian medications (carbidopa/levodopa,
amantadine, bromocriptine, selegiline). Others: amphetamines, amphetamine-like
compounds, appetite suppressants, phenothiazines, reserpine, buspirone, clonidine,
disulfiram, guanethidine, MAO inhibitors, theophylline, tricyclic antidepressants,
salicylates, cholinesterase inhibitors and memantine.

- History of a first-degree family member with early onset (age <60 years) dementia.

- Irregular sleep-wake rhythms (based on the actigraphy recordings) or severe OSA
(AHI4%≥30).

- Chronic use of antidepressants and melatonin are allowed.

- Excessive daytimes sleepiness (Epworth Sleepiness Scale >10) or history of CVE
(arrhythmias, heart valve disease, cardiomyopathy, carotid or coronary artery disease
and chest pain) will not be allowed in the OSA groups.
We found this trial at
1
site
New York, New York 11222
Phone: 212-263-3255
?
mi
from
New York, NY
Click here to add this to my saved trials